Agios Pharmaceuticals, Inc. AGIO

What this company does

Its lead product candidate, mitapivat, is an activator of both wild-type and mutant pyruvate kinase enzymes for the potential treatment of hemolytic anemias, approved under the brand names AQVESME and PYRUKYND in various markets. The company is also developing tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, targeting the TMPRSS6 gene. The company is engaged solely in the discovery and development of medicines in the field of cellular metabolism and operates in one operating segment. As of December 31, 2025, the company had 539 full-time employees and 1 part-time employee, with three employees based in Switzerland and the remainder located in the United States. The company's executive offices are located at 88 Sidney Street, Cambridge, Massachusetts.

Written from the business description in AGIOS PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.